Dengue Vaccine

About VLP Therapeutics

VLP Therapeutics is a clinical-stage biotech advancing a novel vaccine platform centered on self-amplifying RNA (saRNA) with modified nucleosides, such as 5-methylcytidine, to improve safety and immunogenicity. The company has a diversified pipeline including COVID-19, malaria, and dengue vaccines, as well as cancer immunotherapies, supported by partnerships and non-dilutive funding from entities like the Gates Foundation. With operations in the US and Japan, VLPT is positioning itself as a player in the next wave of mRNA and replicon vaccine technology, aiming for broader and more durable immune responses.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company with a bifurcated strategy targeting high-value niches. Its mission is to develop and commercialize novel therapies for rare diseases with significant unmet medical needs, particularly in cutaneous T-cell lymphoma and oral mucositis, while leveraging U.S. government funding to advance a portfolio of biodefense countermeasures. The company's key achievements include positive Phase 3 results for its lead asset, SGX301, and the receipt of multiple government grants and contracts supporting its public health pipeline. Soligenix's strategy is to de-risk development through non-dilutive government funding, advance its late-stage clinical assets toward regulatory submissions, and seek strategic partnerships for commercialization.

Therapeutic Areas